Insulet Co. Shares (NASDAQ:PODD) sold by D1 Capital Partners LP

D1 Capital Partners LP reduced its position in Insulet Co. (NASDAQ:PODD – Free Report) by 72.9% during the second quarter, Holdings Channel.com reports. The fund owned 270,652 shares of the medical instruments supplier’s stock after selling 726,517 shares during the quarter. Insulet makes up 0.9% of D1 Capital Partners LP’s holdings, making the stock its 27th biggest holding. D1 Capital Partners LP’s holdings in Insulet were worth $54,618,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Sunbelt Securities Inc. purchased a new position in shares of Insulet in the first quarter valued at about $29,000. International Assets Investment Management LLC acquired a new stake in Insulet in the second quarter valued at about $32,000. UMB Bank na raised its stake in Insulet by 81.0% in the second quarter. UMB Bank now owns 181 shares of the medical instruments supplier’s stock worth $37,000 after buying an additional 81 shares during the period. Jones Financial Companies Lllp acquired a new stake in shares of Insulet in the fourth quarter valued at $40,000. Finally, CVA Family Office LLC raised its stake in Insulet by 138.1% in the second quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock valued at $50,000 after acquiring an additional 145 shares during the period.

Insulet price performance

Shares of PODD stock opened at $236.58 on Monday. The firm has a fifty day moving average of $202.88 and a two hundred day moving average of $188.48. The firm has a market cap of $16.59 billion, a P/E ratio of 71.69, a P/E/G ratio of 4.38 and a beta of 1.21. Island Co. has a 1 year low of $125.82 and a 1 year high of $243.98. The company has a debt-to-equity ratio of 1.36, a current ratio of 3.60, and a quick ratio of 2.71.

Insulet (NASDAQ:PODD – Get Your Free Report ) last posted its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 EPS for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.01). Insulet had a return on equity of 30.73% and a net margin of 21.11%. The firm had revenue of $488.50 million during the quarter, compared to analyst estimates of $488.00 million. In the same quarter last year, the company posted earnings of $0.38 per share. The company’s revenue for the quarter was up 23.2% year over year. As a group, research analysts anticipate that Insulet Co. will post 3.04 earnings per share for the current fiscal year.

Analysts set new price targets

PODD has been the subject of a number of research reports. Redburn Atlantic started coverage on shares of Insulet in a research report on Thursday, May 30th. They set a “buy” rating and a $235.00 price target for the company. UBS Group upped their price target on Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a research note on Friday, August 9th. BTIG Research cut their price target on Insulet from $270.00 to $250.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. OTR Global restated a “mix” rating on shares of Insulet in a research report on Monday, June 10th. Finally, Barclays boosted their target price on shares of Insulet from $200.00 to $220.00 and gave the stock an “equal weight” rating in a research report on Monday, August 12th. Four investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Moderate Buy” and a consensus price target of $229.21, according to MarketBeat.

Get the latest stock analysis on Insulet

Insulet Company Profile

(Free Report)

Insulet Corporation develops, manufactures and sells insulin delivery systems for people with insulin-dependent diabetes. The company’s Omnipod platform includes the Omnipod 5 automated insulin delivery system (Omnipod 5), which includes a proprietary AID algorithm built into the Pod that integrates with a third-party continuous glucose monitor to obtain glucose readings via Bluetooth wireless communication; Omnipod DASH which features a Bluetooth-enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touchscreen user interface; and the Omnipod GO, a self-contained, wearable insulin delivery system that delivers a fixed rate of continuous rapid-acting insulin for 72 hours.

See Also

Want to see what other hedge funds own PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Insulet Co. (NASDAQ:PODD – Free Report).

Get news and reviews for Insulet Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Insulet and related companies with MarketBeat.com’s FREE daily email newsletter.